Edition:
United States

People: Acceleron Pharma Inc (XLRN.OQ)

XLRN.OQ on NASDAQ Stock Exchange Global Market

48.19USD
7 Dec 2018
Change (% chg)

$-1.77 (-3.54%)
Prev Close
$49.96
Open
$49.62
Day's High
$50.01
Day's Low
$47.47
Volume
130,606
Avg. Vol
128,211
52-wk High
$59.54
52-wk Low
$32.62

McCourt, Thomas 

Mr. Thomas A. McCourt is an Independent Director of the Company. He has served as the senior vice president of marketing and sales and chief commercial officer of Ironwood Pharmaceuticals, Inc. since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt left the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he directed the launch and growth of Zelnorm for the treatment of patients with IBS-C and CIC and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for Prilosec™ and NEXIUM®. Mr. McCourt has a degree in pharmacy from the University of Wisconsin. We believe that Mr. McCourt’s commercial leadership experience and industry experience working for many well established companies qualify him to serve as a member of our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 47,500
Restricted Stock Awards, USD 16,443
Long-Term Incentive Plans, USD --
All Other, USD 57,839
Fiscal Year Total, USD 121,782

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Francois Nader

245,291

Habib Dable

1,322,310

Kevin McLaughlin

1,570,900

John Quisel

1,692,320

Ravindra Kumar

1,510,260

Sujay Kango

--
As Of  30 Dec 2017